NWRN Stock Overview
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, focus on the development of novel therapies for the treatment of central nervous system (CNS) and pain in Italy and the United States.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Newron Pharmaceuticals S.p.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF7.18 |
| 52 Week High | CHF11.45 |
| 52 Week Low | CHF3.70 |
| Beta | 0.70 |
| 1 Month Change | -3.49% |
| 3 Month Change | -10.47% |
| 1 Year Change | 59.56% |
| 3 Year Change | 193.66% |
| 5 Year Change | -21.44% |
| Change since IPO | -86.48% |
Recent News & Updates
Recent updates
Here's Why We Think Newron Pharmaceuticals S.p.A.'s (VTX:NWRN) CEO Compensation Looks Fair for the time being
Apr 11
We Think Newron Pharmaceuticals (VTX:NWRN) Has A Fair Chunk Of Debt
Nov 06Shareholders May Be Wary Of Increasing Newron Pharmaceuticals S.p.A.'s (VTX:NWRN) CEO Compensation Package
Apr 06Newron Pharmaceuticals (VTX:NWRN) Has Debt But No Earnings; Should You Worry?
Apr 01A Look At Newron Pharmaceuticals' (VTX:NWRN) Share Price Returns
Feb 25Shareholder Returns
| NWRN | CH Pharmaceuticals | CH Market | |
|---|---|---|---|
| 7D | -0.6% | -0.9% | -0.9% |
| 1Y | 59.6% | -13.1% | -4.0% |
Return vs Industry: NWRN exceeded the Swiss Pharmaceuticals industry which returned -13.1% over the past year.
Return vs Market: NWRN exceeded the Swiss Market which returned -4% over the past year.
Price Volatility
| NWRN volatility | |
|---|---|
| NWRN Average Weekly Movement | 9.1% |
| Pharmaceuticals Industry Average Movement | 3.3% |
| Market Average Movement | 3.5% |
| 10% most volatile stocks in CH Market | 7.4% |
| 10% least volatile stocks in CH Market | 1.9% |
Stable Share Price: NWRN's share price has been volatile over the past 3 months.
Volatility Over Time: NWRN's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Swiss stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 22 | Stefan Weber | www.newron.com |
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, focus on the development of novel therapies for the treatment of central nervous system (CNS) and pain in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson’s in the European Union, Switzerland, the United Kingdom, the United States of America, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan, and South Korea. The company’s product pipeline includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication.
Newron Pharmaceuticals S.p.A. Fundamentals Summary
| NWRN fundamental statistics | |
|---|---|
| Market cap | CHF133.78m |
| Earnings (TTM) | -CHF15.77m |
| Revenue (TTM) | CHF8.80m |
15.2x
P/S Ratio-8.5x
P/E RatioIs NWRN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NWRN income statement (TTM) | |
|---|---|
| Revenue | €9.06m |
| Cost of Revenue | €0 |
| Gross Profit | €9.06m |
| Other Expenses | €25.28m |
| Earnings | -€16.22m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Sep 19, 2024
| Earnings per share (EPS) | -0.87 |
| Gross Margin | 100.00% |
| Net Profit Margin | -179.13% |
| Debt/Equity Ratio | -160.6% |
How did NWRN perform over the long term?
See historical performance and comparison